These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 30842314)

  • 1. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
    Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
    Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
    Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
    Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
    Kambayana G; Surya Rini S
    Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.
    Gupta S; Simic M; Sagan SA; Shepherd C; Duecker J; Sobel RA; Dandekar R; Wu GF; Wu W; Pak JE; Hauser SL; Lim W; Wilson MR; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36657993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-cell therapy in autoimmune diseases.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
    Paszkiewicz PJ; Fräßle SP; Srivastava S; Sommermeyer D; Hudecek M; Drexler I; Sadelain M; Liu L; Jensen MC; Riddell SR; Busch DH
    J Clin Invest; 2016 Nov; 126(11):4262-4272. PubMed ID: 27760047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.
    Ahuja A; Teichmann LL; Wang H; Dunn R; Kehry MR; Shlomchik MJ
    J Immunol; 2011 Oct; 187(7):3888-94. PubMed ID: 21873531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE.
    Wilhelm A; Chambers D; Müller F; Bozec A; Grieshaber-Bouyer R; Winkler T; Mougiakakos D; Mackensen A; Schett G; Krönke G
    JCI Insight; 2024 May; 9(12):. PubMed ID: 38722688
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice.
    Monneaux F; Dumortier H; Steiner G; Briand JP; Muller S
    Int Immunol; 2001 Sep; 13(9):1155-63. PubMed ID: 11526096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice.
    Gu F; Molano I; Ruiz P; Sun L; Gilkeson GS
    Clin Immunol; 2012 Nov; 145(2):142-52. PubMed ID: 23041504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of B cells in murine lupus: efficacy and resistance.
    Ahuja A; Shupe J; Dunn R; Kashgarian M; Kehry MR; Shlomchik MJ
    J Immunol; 2007 Sep; 179(5):3351-61. PubMed ID: 17709552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
    Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V
    Clin Exp Immunol; 2024 Jun; 217(1):15-30. PubMed ID: 38642912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
    Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y
    Ann Rheum Dis; 2024 Sep; 83(10):1304-1314. PubMed ID: 38777376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of B Cell Depletion by CD19-Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis.
    Avouac J; Cauvet A; Orvain C; Boulch M; Tilotta F; Tu L; Thuillet R; Ottaviani M; Guignabert C; Bousso P; Allanore Y
    Arthritis Rheumatol; 2024 Feb; 76(2):268-278. PubMed ID: 37610259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
    Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
    Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.